Introduction
============

Interethnic differences in drug-metabolizing enzyme activity have been associated with inter-individual differences in the efficacy and toxicity of many medications ([@b1-mmr-16-01-0573]). Among drug-metabolizing enzymes, the cytochrome *P450 (CYP)*, a supergene family involved in the phase I reactions of the metabolism of several drugs and endogenous compounds, has increasingly been recognized to have clinically significant consequences ([@b2-mmr-16-01-0573]). Cytochrome *P450 1A2 (CYP1A2)*, one of the *CYP* enzyme isoforms, is of particular interest because it exhibits a genetic polymorphism.

*CYP1A2*, mapped to the positive strand of the long arm of chromosome 15 at 15q24.1, is predominantly expressed in the human liver and at lower levels in intestine, pancreas, lung and brain ([@b3-mmr-16-01-0573]). The human *CYP1A2* enzyme has been demonstrated to be responsible for many commonly used drugs, including caffeine, imipramine, paracetamol, clozapine, theophylline, tacrine, phenacetin and some neurotoxins ([@b4-mmr-16-01-0573]). In addition, *CYP1A2* is known to gain further importance in the metabolic activation of numerous carcinogens ([@b5-mmr-16-01-0573]). Therefore, any alteration to *CYP1A2* activity has been suggested to be a susceptibility factor for drug metabolism and the etiology of developing cancers and other diseases ([@b6-mmr-16-01-0573]).

Like other drug metabolizing enzymes, numerous factors have been presented to elucidate the mechanisms underlying the inter-individual differences in *CYP1A2* activity, such as race, gender, environmental exposure to inducers or inhibitors and genetic factors ([@b7-mmr-16-01-0573]). With respect to genetic factors, several alleles and additional haplotype variants have been identified in coding and non-coding regions of the *CYP1A2* gene, in particular in the *CYP1A2* upstream sequence and the intron 1 region (*CYP* allele nomenclature website at <http://www.cypalleles.ki.se/>). The frequencies of these polymorphisms display interethnic variability particularly between those of European and East Asian ancestry ([@b8-mmr-16-01-0573]).

Tibet, as a part of China, contains a large number of high altitude populations that have a distinctive suite of physiological traits that enable them to tolerate environmental hypoxia. Because few data are available on the investigation of the *CYP1A2* genotype in the Tibetan population, the aim of the present study was to determine the *CYP1A2* genotype profile of a random Tibet population by screening for the main allelic variants and compare to the allelic frequencies of those previously reported from other ethnic groups. It is hoped that the results will prospectively offer a preliminary basis for more rational usage of drugs that are substrates for *CYP1A2*.

Materials and methods
=====================

### Subjects and DNA extraction

A total of 96 unrelated Chinese healthy volunteers (48 males and 48 females) of Tibetan origin, mostly students or employees at Xizang Minzu University (Xi\'an, China), were enrolled in the study. All of the individuals lived in the same region at the time of the study and were of Tibetan ancestry without any known ancestry from other ethnicities. The study protocol was approved by The Human Research Committee of Xizang Minzu University (Xi\'an, China), and each volunteer gave written informed consent to participate in the study. Peripheral blood samples were collected and stored after centrifugation at −70°C until analysis, and genomic DNA was isolated and purified using a commercial blood Genomic DNA extraction kit (Xi\'an GoldMag Nanobiotech Co., Ltd., Xi\'an, China) according to the manufacturer\'s recommendations.

### Polymerase chain reaction (PCR) and DNA sequencing

The primer pairs designed to amplify the 5′ flanking regions, all exons and all introns of the *CYP1A2* gene are listed in [Table I](#tI-mmr-16-01-0573){ref-type="table"}. The PCR was conducted in a total volume of 10 µl consisting of 1 µl genomic DNA (20 ng/µl), 0.5 µl each primer pair (5 µM), 5 µl HotStart TaqMasterMix (Qiagen China Co., Ltd., Shanghai, China), and 3 µl deionized water. PCR amplification consisted of an initial denaturation step at 95°C for 15 min followed by 35 cycles of denaturation at 95°C for 30 sec, annealing at 55--64°C for 30 sec, extension at 72°C for 1 min. The final extension step was performed at 72°C for 3 min. The PCR products were purified and sequenced on an ABI Prism 3100 sequencer (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA) using a BigDye Terminator Cycle Sequencing kit (version, 3.1; Applied Biosystems; Thermo Fisher Scientific, Inc.).

### Statistical analysis

The sequences were edited and assembled using Sequencher software (version, 4.10.1; Gene Codes Corporation, Ann Arbor, MI, USA). Allele nomenclature was assigned according to the Human Cytochrome *P450 (CYP)* Allele Nomenclature Committee (<http://www.cypalleles.ki.se/>). Differences in allele frequencies between Tibet and other ethnic populations were measured by Fisher exact test. P\<0.05 was considered to indicate a statistically significant difference. The observed genotype frequencies of *CYP1A2* were also estimated by the Hardy Weinberg law for the predicted frequencies. The linkage equilibrium (LD) coefficient (D\') between each genetic variant was analyzed by Haploview software (version, 4.1; Daley Lab at the Broad Institute, Cambridge, MA, USA).

### Protein prediction of novel mutations

PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph/>) and SIFT (<http://blocks.fhcrc.org/sift/SIFT.html>) software were performed to predict the effect of missense variants on the protein function. Based on the SIFT score, SIFT scores ≤0.05 were predicted by the algorithm to be evolutionary conservation and intolerance to substitution, whereas scores \>0.05 were considered tolerant (not likely to affect protein function) ([@b9-mmr-16-01-0573]). The PolyPhen-2 score ranges from 0 to 1, and PolyPhen-2 scores \>0.85, between 0.85 and 0.15, and \<0.15 were coded as 'probably damaging', 'possibly damaging' and 'benign', respectively ([@b10-mmr-16-01-0573]).

Results
=======

### Single nucleotide polymorphism (SNP) discovery

In the current study, the authors used direct sequencing to analyze sequence variation within the *CYP1A2* gene among 96 healthy Tibetans. The analyses covered the proximal promoter region, all exons as well as surrounding intronic regions and variable lengths of the flanking regions. [Table II](#tII-mmr-16-01-0573){ref-type="table"} presented all the *CYP1A2* mutation variations in this population. The most frequent polymorphism was the C-163A change in intron 1 which had 88.54% frequency, followed by G2321C change in intron 4 which had 37.5% frequency and T-739G change in intron 1 which had 20.83% frequency in the healthy group. Both 2159G\>A and 5347C\>T had similar results (13.5%), correspondingly. Additionally, among a total of 14 nucleotide variants detected, the authors detected three novel *CYP1A2* variants (795G\>C, 1690G\>A and 2896C\>T) in exon 2 and intron 5 region with minor allele frequency of 1.04%, of which one variant (795G\>C) resulted in an amino acid change from glutamine to histidine at position 265.

### Allele & genotype frequencies

A total of eight different *CYP1A2* alleles and genotypes were determined based on the polymorphisms identified in the current study ([Table III](#tIII-mmr-16-01-0573){ref-type="table"}). Hardy-Weinberg equilibriums were assessed and all *CYP1A2* allele and genotype frequencies were in accordance with the Hardy-Weinberg equilibrium. The wild-type allele, *CYP1A2*\* *1A*, with a frequency of 6.77%, was classified as normal enzyme activity. Besides the wild-type allele, *CYP1A2*\* *1B* (58.33%) and *CYP1A2*\**1F* (14.58%) were the best-characterized defect alleles in the Chinese Tibetan population, of which *CYP1A2*\**1F* alleles were putatively linked to higher inducibility of the enzyme. *CYP1A2*\**1G*, *CYP1A2*\**1J*, *CYP1A2*\**1M*, *CYP1A2*\**13* and *CYP1A2*\**14* alleles have been included in the table, as these were the most scarce alleles in the study population. They occurred at a frequency of 1.56--5.21% in the current study population.

In relation to genotypes, the most frequent genotypes were \* *1A/*\* *1B* (13.54%), \* *1B/*\* *1B* (16.67%) and \* *1B/*\* *1F* (29.17%) ([Table III](#tIII-mmr-16-01-0573){ref-type="table"}). All five other genotypes presented frequencies of \<10.5% in the study. In addition, individuals with the \* *1B/*\* *1B* genotype have been associated with a higher activity of the enzyme.

### Interethnic variability

In order to better understand the occurrence and distributional patterns of the common mutation allele amongst different ethnic groups, the data were compared with those from previous investigations in different countries and ethnic groups in Caucasians, Africans, Arabs and Asians ([Table IV](#tIV-mmr-16-01-0573){ref-type="table"}). C-163A (88.54%) was most frequent among the Tibetan population, when compared with T-739 G (20.83%) and C5347T (13.54%). The allele frequency of C-163A and T-739G was significantly higher than that in Caucasians, Africans, Arabs and Asians, but allelic distributions of C-163A were relatively equal to that in Malays (78%), and T-739G was relatively similar to Tunisia (13.5%), Southern Chinese (9.3%) and Indians (10%). For C5347T, Tibetans demonstrated a relatively lower frequency of mutation compared with Caucasians (48--64.4%), but was similar to that in Africans (20.9%) and Asians (12.0--20.4%) with the only exception of South Asians (35%), which was significantly higher than Tibetans.

### LD analysis

To identify relationships between the SNPs identified in the polymorphism screening, linkage disequilibrium (LD) analysis was evaluated in Haploview (<http://www.broad.mit.edu/mpg/haploview/>) using coefficient of linkage disequilibrium D\' values ([Fig. 1](#f1-mmr-16-01-0573){ref-type="fig"}). Even though no distinct LD blocks or extended haplotypes could be detected in the sequenced data, some SNPs were identified (−739T\>G and 1202C\>T, −163C\>A and 2321G\>C, 1202C\>T and 3613T\>C, −739T\>G and 3613T\>C, −739T\>G and 5112C\>T) seemed to be linked with high D\'.

### Protein function prediction of non-synonymous mutation

The SIFT scores for the amino acid substitutions Val75Ile (223G\>A), Gln265His (novel variant 795G\>C), Gly299Ser (1514G\>A) and Arg356Gln (2410G\>A), ranged between 0.07 and 0.72 and were predicted as being tolerated. In contrast, the Thr438Ile (5112C\>T) mutations gave SIFT scores of 0.00, predicting they were highly likely to affect protein function. To validate the prediction of SIFT scores, the PolyPhen-2 algorithm was used to predict variations Val75Ile, Gln265His, Gly299Ser and Arg356Gln as benign with scores of 0.415, 0.039, 0.045 and 0.002, respectively, and Thr438Ile as possibly damaging, with a score of 0.281. Four substitutions (Gln265His, Gly299Ser, Arg356Gln and Thr438Ile) were consistently computationally predicted using both PolyPhen-2 and SIFT, while Val75Ile was not consistent. The protein function prediction of variants 5112C\>T and 795G\>C (novel variant) is presented [Fig. 2](#f2-mmr-16-01-0573){ref-type="fig"} (PolyPhen-2).

Discussion
==========

*CYP1A2*, one of the major P450 isoforms, accounts for \~5--20% of the total hepatic *CYP* content and contributes to the metabolism of 10% of clinically relevant drugs, including clozapine and caffeine ([@b3-mmr-16-01-0573]). It has been demonstrated that *CYP1A2* activity has been influenced by the presence of polymorphic variants, which displays wide interindividual and interethnic variability. In the present study, the *CYP1A2* gene polymorphisms were systematically screened in 96 healthy Chinese Tibetan subjects. To the best of the authors\' knowledge, these efforts are the first to investigate allelic variants of *CYP1A2* among the Tibetan population to date.

A total of 14 SNPs were detected in the current study. There were eight SNPs detected in the intron region. The −163 C\>A (\* *1F/*\* *1J/*\* *1K/*\* *1M* allele) in intron 1 is the most common *CYP1A2* polymorphism in various population studies ([Table IV](#tIV-mmr-16-01-0573){ref-type="table"}). In Tibetans, −163C\>A is the most frequently observed SNP, with an overall frequency of 88.54%, which is significantly higher than that in Caucasians, Africans, Arabs and Asians (except Malays). Possible explanations for these differences include: Genetic background, cultural variants and other factors, such as living environment, medication use, body composition and dietary habits ([@b11-mmr-16-01-0573],[@b12-mmr-16-01-0573]). In addition, much confusion and controversy still arises as to the available data in literature about the functional consequences and allele frequencies of *CYP1A2* variants, mainly because of limitation of sample size and the differing designations of the *CYP1A2*\* *1F* allele (defined as having-163A by The HumanCytochrome P450 Allele Nomenclature Committee). Sachse *et al* ([@b4-mmr-16-01-0573]) first reported that smokers homozygous for the *C*-allele had, on average, 40% lower CYP1A2 activity in comparison with those with the *A/A* genotype. In contrast, some inconsistent studies have reported that *CYP1A2* \* *1F* mutation was associated with a high inducibility of *CYP1A2* in smokers as well as in nonsmokers ([@b13-mmr-16-01-0573]). It is tempting to speculate the divergence may be the possibility of the −163C\>A occurring in linkage disequilibrium with another mutation that is responsible for the increased *CYP1A2* inducibility ([@b14-mmr-16-01-0573]). The present study identified a strong linkage disequilibrium between −163C\>A and 2321G\>C polymorphisms ([Fig. 1](#f1-mmr-16-01-0573){ref-type="fig"}), providing researchers in the field with abundant clues, however, more studies are required to shed more light on this idea. Another most prevalent polymorphism in intron 1 region, −739T\>G, was first reported in in a Japanese population ([@b5-mmr-16-01-0573]). −739T\>G is located on the *CYP1A2*\* *1E*, \* *1G*, \* *1J* or \* *1K* allele, and previous research demonstrated that this polymorphism has no effect on the enzyme activity ([@b6-mmr-16-01-0573]). −739T\>G is the most common variant among Asians and the frequency of 20.83% found in the present study is significantly higher than other Asians ([Table IV](#tIV-mmr-16-01-0573){ref-type="table"}), Caucasians (0.77--5%) ([@b6-mmr-16-01-0573],[@b8-mmr-16-01-0573]), Africans (6.6--13.5%) ([@b15-mmr-16-01-0573],[@b16-mmr-16-01-0573]) and Arabs studied elsewhere (3--10%) ([@b17-mmr-16-01-0573],[@b18-mmr-16-01-0573]). Interethnic differences in the prevalence of −739T\>G may be one of the major factors to consider in large pharmacogenetic studies and clinical applications in populations of Asian ancestry, such as Chinese Tibetans, since the proportion of high expressers due to the presence of −739T\>G varies depending on the ethnic background. Among the six SNPs identified in the exons, the synonymous 5347T\>G (\* *1B/*\* *1G/*\* *1H*), was the most common variant among Caucasians and the frequency of 13.54% identified in the present study presented a frequency significantly lower than Caucasians, but it was quite similar to Asians (except South Asians) ([Table IV](#tIV-mmr-16-01-0573){ref-type="table"}). This may be because these populations are distributed in different geographical regions, which may result in the formation of numerous, small, genetically isolated groups.

In the tested Chinese Tibetan population, *CYP1A2*\* *1A* is referred to as the wild-type allele with a frequency of 6.77%, which is significantly less when compared with Swedes (24.4%), Koreans (21.7%), Japanese (34.8%), Caucasians (33.4%) and Serbs (33.4%) ([@b19-mmr-16-01-0573]--[@b21-mmr-16-01-0573]). The occurrence of the most prevalent defective alleles, *CYP1A2*\* *1B* (5347T\>G), evaluated in Chinese Tibetan subjects (58.3%) in the present study is slightly lower compared to the occurrence reported in Caucasians (61.8%), but is higher than other Chinese population (20.4%) ([@b22-mmr-16-01-0573]). However, the genotype frequencies observed for \* *1B*, \* *1B* in Tibetans (16.67%) was slightly higher than that in Caucasian (6.19%), Japanese (7.5%), Korean (10.75%) and other Chinese population (9%). Currently, only Chen *et al* ([@b22-mmr-16-01-0573]) reported that CYP1A2\*1B homozygotes demonstrated marginally higher CYP1A2 activity, when compared with *CYP1A2*\* *1A/*\* *1A* homozygotes ([@b22-mmr-16-01-0573]). Because the \* *1B*, \* *1B* genotype is relatively common in Chinese Tibetan subjects, this genotype may have a major influence in altered *CYP1A2* activity, of course, this requires further investigation. *CYP1A2*\* *1F* resulted from a C\>A substitution at −163 in intron 1 of the promoter region. The haplotype \*1F allele is common with high and comparable frequencies in various studies. However, the frequencies of *CYP1A2*\* *1F* (−163A allele) in Tibetans is 14.58%, which was far less frequent compared with Caucasians (73.7%) ([@b23-mmr-16-01-0573]), Africans (61%) ([@b24-mmr-16-01-0573]), Arabs (68%) ([@b17-mmr-16-01-0573]) and Asians (69.3%) ([@b23-mmr-16-01-0573]). Since *CYP1A2*\* *1F* is reported to be associated with an effect on enzyme inducibility, the estimates of their frequencies in the Tibetan population may be of extreme importance. Compared with the alleles *CYP1A2*\* *1B* and *CYP1A2*\* *1F*, \* *1G*, \* *1J*, \* *1M*, \* *13* and \* *14* are relatively rare in Tibetans, thus the clinical applicability of this pharmacogenetic testing seems to be limited to a small number of individuals. In addition, the-163C\>A variant is present in the CYP1A2\*1F allele, but it is also presented in several other CYP1A2 haplotypes, two of which (*CYP1A2*\* *1J* and \* *1M*) were identified in the sample population. Therefore, it is informative to take the complete haplotypes into consideration when investigating associations of phenotype rather than focusing on single SNPs.

After systematically screening the polymorphisms of the *CYP1A2* gene in the healthy population of Chinese Tibetan subjects, three novel variants were detected that included one nonsynonymous change at position G795C in exon 2. These variants are rare but not absent, occurring in \<1.04% of the population, but the current study is the first to report these variants in Chinese Tibetan subjects. Although the c.795 G\>C variation is predicted to not have an affect on protein function by the SIFT or PolyPhen algorithms, further functional studies are still necessary to clarify the role of their clinical significance.

It should be acknowledged that the current research was designed to investigate the unique distribution of the *CYP1A2* alleles in the Tibetan population. The characterization of *CYP1A2* genetic polymorphisms among different races may contribute to the outcome and risks to certain drug therapies.
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![Linkage disequilibrium analysis of CYP1A2. LD is displayed by standard color schemes, with bright red for very strong LD (LOD \>2, D\'=1), pink red (LOD \>2, D\'\<1) and blue (LOD \<2, D\'=1) for intermediate LD, and white (LOD \<2, D\'\<1) for no LD. LD linkage equilibrium; LOD, logarithm of odds score; D\', coefficient of linkage disequilibrium.](MMR-16-01-0573-g00){#f1-mmr-16-01-0573}

![Protein prediction of the variants 795G\>C (novel mutation) and 5112C\>T using the PolyPhen-2 tool. (A) Prediction of the novel mutation 795G\>C (B) Prediction of the variant 5112C\>T.](MMR-16-01-0573-g01){#f2-mmr-16-01-0573}

###### 

Primers used for human CYP1A2 gene amplification.

  Region        Primer sequence (5′-3′)     Fragment size (bp)
  ------------- --------------------------- --------------------
  CYP1A2_1\_F   AATCGATATGGCAATCAAATGCAAA   
  CYP1A2_1\_R   CCCGTCTTTCTGTCCCCACT        740
  CYP1A2_2\_F   TAGGCTCCCTACCCTGAACC        
  CYP1A2_2\_R   AACATGAACGCTGGCTCTCT        919
  CYP1A2_3\_F   GTCACTGGGTAGGGGGAACT        
  CYP1A2_3\_R   AAGGTGTTGAGGGCATTCTG        896
  CYP1A2_4\_F   CTGGCACTGTCAAGGATGAG        
  CYP1A2_4\_R   ATTGCAGGACTCTGCTAGGG        909
  CYP1A2_5\_F   CAGGACTTTGACAAGGTGAGC       
  CYP1A2_5\_R   CATAGCCCAGGCTCAAACC         912
  CYP1A2_6\_F   CCTGTTCAAGCACAGCAAGA        
  CYP1A2_6\_R   AACACAGAGGACAAGCAGAGC       903
  CYP1A2_7\_F   CCTGTTATGTGCCTGCTGTG        
  CYP1A2_7\_R   GGGGATTCAGGCCTCTTACT        899
  CYP1A2_8\_F   TCCCAGTGCCCTCTGTGCCA        
  CYP1A2_8\_R   GCCTTCCTGACTGCTGAACCTGC     848
  CYP1A2_9\_F   AACAGCCAAGTGCGCAGCCA        
  CYP1A2_9\_R   TCGCCTGAGGTACCCCACCT        881
  CYP1A2_10_F   AGGTGGGGTACCTCAGGCGA        
  CYP1A2_10_R   GAGGTGCCTGGGGGAGGGAG        930
  CYP1A2_11_F   TTTGGTTCCTTCCCACCTACCCTT    
  CYP1A2_11_R   GAAGAGAAACAAGGGCTGAGTCCCC   511
  CYP1A2_12_F   TGCTGTTTGGCATGGGCAAG        
  CYP1A2_12_R   TCTGGTGATGGTTGCACAATTC      926
  CYP1A2_13_F   AGAATTGTGCAACCATCACCAGAA    
  CYP1A2_13_R   CCAGTCTCAGGACTCAAGCACCA     921

CYP, cytochrome P450.

###### 

CYP1A2 polymorphisms and their frequencies in a Chinese Tibetan population.

  Polymorphism   Location   Flanking sequence         Minor allele   CYP nomenclature       Reference dbSNP   Amino acid translation   Predicted effect on protein structure/function using PolyPhen   Frequency (%)
  -------------- ---------- ------------------------- -------------- ---------------------- ----------------- ------------------------ --------------------------------------------------------------- ---------------
  −739T\>G       Intron 1   GGTGTAGGGG K CCTGAGTTCC   G              CYP1A2\*1E/\*1G/\*1J   rs2069526         /                                                                                        20.83
  −163C\>A       Intron 1   CTCTGTGGGC M CAGGACGCAT   A              CYP1A2\*1F/\*1J/\*1K   rs762551          /                                                                                        88.54
  223G\>A        Exon 2     CTACGGGGAC R TCCTGCAGAT   A                                     rs150164960       Val75Ile                 Benign                                                          1.04
  795G\>C        Exon 2     GGTTCCTGCA S AAAACAGTCC   C              Novel                  Novel             Gln265His                Benign                                                          1.04
  1202C\>T       Intron 2   TTCACACTAA Y CTTTTCCTTC   T                                     rs4646425         /                                                                                        9.38
  1514G\>A       Exon 3     TAGAGCCAGC R GCAACCTCAT   A              CYP1A2\*13             rs35796837        Gly299Ser                Benign                                                          3.13
  1690G\>A       Intron 3   ACAACATACT R AGATCTGGCT   A              Novel                  Novel             /                                                                                        1.04
  2159G\>A       Intron 4   GAAGCCTTGA R ACCCAGGTTG   A              CYP1A2\*1M/\*1Q/\*17   rs2472304         /                                                                                        13.54
  2321G\>C       Intron 4   TGGGGTATAA S AGGGGATAAT   C                                     rs3743484         /                                                                                        37.50
  2410G\>A       Exon 5     AGGGAGCGGC R GCCCCGGCTC   A                                     rs55918015        Arg356Gln                Benign                                                          4.17
  2896C\>T       Intron 5   AATGCCGACA Y GAGCTTCCTC   T              Novel                  Novel             /                                                                                        1.04
  3613T\>C       Intron 6   GAACTGTTTA Y ATAATGAAAG   C                                     rs4646427         /                                                                                        9.38
  5112C\>T       Exon 7     GCCGATGGCA Y TGCCATTAAC   T              CYP1A2\*14             rs45486893        Thr438Ile                Possibly damaging                                               9.38
  5347C\>T       Exon 7     TCTCCATCAA Y TGAAGAAGAC   T              CYP1A2\*1B/\*1G/\*1H   rs2470890         Asn516=                                                                                  13.54

CYP, cytochrome P450; dbSNP, The Single Nucleotide Polymorphism Database.

###### 

Allele and genotype frequencies of CYP1A2 variants in Chinese Tibetan subjects.

  Allele      Total (n=192)   Phenotype             Frequency (%)
  ----------- --------------- --------------------- ---------------
  \*1A          13            Normal                6.771
  \*1B        112             /                     58.333
  \*1F          28            Higher inducibility   14.583
  \*1G          10            /                     5.208
  \*1J          10            /                     5.208
  \*1M          7             /                     3.646
  \*13          3             /                     1.563
  \*14          9             /                     4.688
                                                    
  Genotype    Total (n=96)    Phenotype             Frequency (%)
                                                    
  \*1A/\*1B   13              /                     13.542
  \*1B/\*1B   16                Higher activity     16.667
  \*1B/\*1F   28              /                     29.167
  \*1B/\*1G   10              /                     10.417
  \*1B/\*1J   10              /                     10.417
  \*1B/\*1M     7             /                     7.292
  \*1B/\*13     3             /                     3.125
  \*1B/\*14     9             /                     9.375

###### 

Distribution of mutant allele frequencies of CYP1A2 −739T\>G, −163C\>A and 5347C\>T in different ethnicities.

  Ethnic group      Study population no.   −163C\>A (\*1F/\*1J/\*1K)                              −739T\>G (\*1E/\*1G/\*1J)                              5347C\>T (\*1B/\*1H/\*1G)                              Reference
  ----------------- ---------------------- ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------ -----------------------------------------------------------------------------------------
  Tibetan           96                     88.54                                                  20.83                                                  13.54                                                  Present study
  Caucasian                                                                                                                                                                                                     
    British         65                     66.2^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   0.77^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   ND                                                     PMID: 12534642
    Bulgarian       138                    72.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   ND                                                     ND                                                     PMID: 18021343
    Caucasian       495                    68.2^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   1.6^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^    ND                                                     PMID: 16307269
    Caucasian       194                    73.7^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   4.1^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^    64.4^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   PMID: 18231117
    Caucasian       236                    68.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   ND                                                     ND                                                     PMID: 10233211
    Costa Rican     932                    60.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   ND                                                     ND                                                     PMID: 15466009
    European        166                    69.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   5.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^    48.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   PMID: 22948892
    German          150                    68.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   ND                                                     ND                                                     PMID: 21918647
    Hawaiian        194                    71.4^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   ND                                                     ND                                                     PMID: 12925300
    Hungarian       396                    68.6^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   ND                                                     ND                                                     PMID: 25461540
    Italian         95                     66.8^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   ND                                                     ND                                                     PMID: 16188490
    Roman           404                    56.9^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   ND                                                     ND                                                     PMID: 25461540
    Serbian         262--264               61.1^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   3.4^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^    ND                                                     PMID: 20390257
    Swedish         194                    71.4^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   2.3^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^    ND                                                     PMID: 17370067
    Swedish         1170                   71.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   ND                                                     ND                                                     PMID: 12445029
    Spanish         117                    2.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^    2.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^    ND                                                     PMID: 12920202
    Swiss           100                    68.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   ND                                                     ND                                                     PMID: 12851801
    Turkish         101                    73.2^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   1.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^    ND                                                     PMID: 20797314
    Turkish         110                    73.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   1.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^    ND                                                     PMID: 18825963
    Turkish         146                    66.8^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   4.8^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^    49.7^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   PMID: 19450128
  African                                                                                                                                                                                                       
    Ethiopia        173                    60.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   10.0^[a](#tfn5-mmr-16-01-0573){ref-type="table-fn"}^   ND                                                     PMID: 12920202
    Ethiopia        50--391                51.3^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   6.6^[a](#tfn5-mmr-16-01-0573){ref-type="table-fn"}^    20.9                                                   PMID: 20881513 a genomic biography of the gene behind the human drugmetabolizing enzyme
    Tanzanian       71                     49.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   ND                                                     ND                                                     PMID: 15387446
    Tunisia         98                     44.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   13.5                                                   ND                                                     PMID: 19332078
    Tunisia         27                     59.3^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   ND                                                     ND                                                     PMID: 25921178
    South African   983                    61.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   ND                                                     ND                                                     PMID: 22118051
    Ovambo          177                    46.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   ND                                                     ND                                                     PMID: 16933202
    Zimbabwean      143                    57.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   ND                                                     ND                                                     PMID: 15387446
  Arab                                                                                                                                                                                                          
    Egyptian        212                    68.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   3.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^    ND                                                     PMID: 12630986
    Saudi Arabian   136                    10.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   10.0^[a](#tfn5-mmr-16-01-0573){ref-type="table-fn"}^   ND                                                     PMID: 12920202
    Jordanian       550--560               67.3^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   6.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^    ND                                                     PMID: 22426036
  Asian                                                                                                                                                                                                         
    Zhejiang        43                     57.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   ND                                                     ND                                                     PMID: 25117321
  Chinese                                                                                                                                                                                                       
    Chinese         38--42                 71.0^[a](#tfn5-mmr-16-01-0573){ref-type="table-fn"}^   4.0^[a](#tfn5-mmr-16-01-0573){ref-type="table-fn"}^    12.0                                                   PMID: 20930417
    Chinese         168                    67.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   ND                                                     ND                                                     PMID: 11470995
    Chinese         79                     66.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   ND                                                     ND                                                     PMID: 12445035
    Chinese         200                    69.3^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   10.4^[a](#tfn5-mmr-16-01-0573){ref-type="table-fn"}^   15.3                                                   PMID: 18231117
    South           27                     70.4^[a](#tfn5-mmr-16-01-0573){ref-type="table-fn"}^   9.3                                                    20.4                                                   PMID: 16153396
  Chinese                                                                                                                                                                                                       
    Taiwan          204--208               35.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   9.7^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^    14.0                                                   PMID: 21121774
    Indians         41--42                 58.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   10.0                                                   12.0                                                   PMID: 20930417
    Malays          38--42                 78.0                                                   7.0^[a](#tfn5-mmr-16-01-0573){ref-type="table-fn"}^    18.0                                                   PMID: 20930417
    Mongolian       153                    21.2^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   ND                                                     ND                                                     PMID: 16933202
    Japanese        160                    70.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   1.9^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^    18.7                                                   PMID: 18231117
    Japanese        250                    62.8^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   3.2^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^    19.2                                                   PMID: 15770072
    Japanese        159                    61.3^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   8.2^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^    ND                                                     PMID: 10551315
    Korean          150                    62.7^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   2.7^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^    ND                                                     PMID: 17370067
    Korean          1015                   62.5^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   ND                                                     ND                                                     PMID: 19579025
    Korean          250                    31.6^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   ND                                                     ND                                                     PMID: 16933202
    Korean          160--186               66.1^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   5.4^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^    18.3                                                   PMID: 18231117
    South Asian     166                    38.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   6.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^    35.0^[b](#tfn6-mmr-16-01-0573){ref-type="table-fn"}^   PMID: 22948892

ND, not determined.

P\<0.05 vs. the Tibetan population

P\<0.01 vs. the Tibetan population.

[^1]: Contributed equally
